Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease

Abstract

Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel.